We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ten-year Experience of Bexarotene Therapy for Cutaneous T-cell Lymphoma in Finland.
- Authors
Väkevä, Liisa; Ranki, Annamari; Hahtola, Sonja
- Abstract
Bexarotene is an oral retinoid shown to be active against the cutaneous manifestations of cutaneous T-cell lymphoma (CTCL). Literature on the efficacy, dosing and side-effects of bexarotene is sparse. We present here data on 37 Finnish patients with CTCL treated with bexarotene during the last 10 years. Bexarotene was equally effective as monotherapy or when combined with other treatment modalities, resulting in overall responses of approximately 75%. Early-stage CTCL responded better than advanced-stage CTCL (83% vs. 33%). The mean time to observable response was 3 months and the mean duration of the response was 21 months. The dose of bexarotene was generally lower than recommended due to side-effects. Abrupt elevation of liver transaminases, resulting in cessation of treatment, was observed in 4 (11%) patients. We conclude that the dose of bexarotene should be titrated individually to achieve optimal results. Maintenance therapy with low-dose bexarotene is a feasible alternative.
- Subjects
FINLAND; SKIN disease treatment; T-cell lymphoma; ORAL medicine; RETINOIDS; DRUG dosage; LIVER enzymes; AMINOTRANSFERASES
- Publication
Acta Dermato-Venereologica, 2012, Vol 92, Issue 3, p258
- ISSN
0001-5555
- Publication type
Article
- DOI
10.2340/00015555-1359